Fiera Capital Corp Sells 10,561 Shares of Insmed Incorporated (NASDAQ:INSM)

Fiera Capital Corp lessened its position in shares of Insmed Incorporated (NASDAQ:INSM) by 1.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 581,854 shares of the biopharmaceutical company’s stock after selling 10,561 shares during the period. Fiera Capital Corp owned 0.33% of Insmed worth $40,171,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of INSM. V Square Quantitative Management LLC acquired a new stake in Insmed during the third quarter worth approximately $30,000. GAMMA Investing LLC boosted its holdings in shares of Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 224 shares in the last quarter. Spire Wealth Management acquired a new stake in shares of Insmed during the 4th quarter worth approximately $47,000. Exchange Traded Concepts LLC increased its stake in shares of Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 627 shares in the last quarter. Finally, JCIC Asset Management Inc. acquired a new position in shares of Insmed during the 3rd quarter valued at $133,000.

Insmed Stock Down 1.2 %

INSM opened at $78.67 on Friday. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $82.04. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company’s 50-day moving average is $73.23 and its 200 day moving average is $73.20. The firm has a market capitalization of $14.07 billion, a P/E ratio of -14.17 and a beta of 1.11.

Analysts Set New Price Targets

A number of equities research analysts have commented on INSM shares. Morgan Stanley raised their price target on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Guggenheim raised their target price on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Friday, February 7th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. Truist Financial reissued a “buy” rating and issued a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. upped their target price on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $85.60.

Insiders Place Their Bets

In related news, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $69.91, for a total transaction of $1,310,812.50. Following the completion of the sale, the chief executive officer now owns 384,960 shares in the company, valued at approximately $26,912,553.60. This trade represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Martina M.D. Flammer sold 33,055 shares of Insmed stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $80.90, for a total transaction of $2,674,149.50. Following the completion of the sale, the insider now directly owns 138,053 shares in the company, valued at approximately $11,168,487.70. This represents a 19.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 495,135 shares of company stock valued at $38,409,713 in the last 90 days. 4.60% of the stock is currently owned by corporate insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.